Xin Wang

Biography

Xin Wang gained her MD at the age of 21 years from Hebei Medicine University in China. She specialized as neurologist to study cerebrovascular diseases. The project, stroke rehabilitation, awarded the First Prize of excellent paper in the Third Annal National Neurologic Rehabilitation meeting. After ten years clinical medicine practicing, including clinical research, she pursued PhD on Medical Science from Institute on Aging and Adaptation, Graduate School of Medicine, Shinshu University in Japan. During PhD course, she discovered an acute leukemia associated brain-specific gene and was the first one who studied its function at molecular & cellular biology level. The first postdoctoral training in NIH/NCI-Frederick in US, gave her an opportunity to complete a publication studying mouse model related to cardiovascular dysfunction that had been pointed as 'must reads' by Faculty1000. In Dental School & Medical School of University of Maryland, Baltimore, Xin studied head & neck cancer and prostate cancer with human specimen, cancer cell lines and animal models. Her summary of a project about tumor microenvironment as primary author gained Minority Scholar Award in AACR meeting. She is the CEO and CSO in biotechnology company, ACURE TECHNOLOGY, Inc. that she is the founder, to develop and discover stem cell therapeutic products based on her extensive medical research experiences. She has published more than 20 peer-reviewed papers in scientific journals ls. Xin Wang gained her MD at the age of 21 years from Hebei Medicine University in China. She specialized as neurologist to study cerebrovascular diseases. The project, stroke rehabilitation, awarded the First Prize of excellent paper in the Third Annal National Neurologic Rehabilitation meeting. After ten years clinical medicine practicing, including clinical research, she pursued PhD on Medical Science from Institute on Aging and Adaptation, Graduate School of Medicine, Shinshu University in Japan. During PhD course, she discovered an acute leukemia associated brain-specific gene and was the first one who studied its function at molecular & cellular biology level. The first postdoctoral training in NIH/NCI-Frederick in US, gave her an opportunity to complete a publication studying mouse model related to cardiovascular dysfunction that had been pointed as 'must reads' by Faculty1000. In Dental School & Medical School of University of Maryland, Baltimore, Xin studied head & neck cancer and prostate cancer with human specimen, cancer cell lines and animal models. Her summary of a project about tumor microenvironment as primary author gained Minority Scholar Award in AACR meeting. She is the CEO and CSO in biotechnology company, ACURE TECHNOLOGY, Inc. that she is the founder, to develop and discover stem cell therapeutic products based on her extensive medical research experiences. She has published more than 20 peer-reviewed papers in scientific journals ls.

Research Interest

 cerebrovascular diseases,bacteriology,pathology